CIK 0001048477
- Large accelerated filer
BIOMARIN PHARMACEUTICAL INC
Sign in to watch- Ticker
- BMRN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 680397820
- Phone
- +1 415-506-6700
- Business address
- 105 DIGITAL DRIVE, NOVATO, CA, 94949
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,466,459
- in 2 filings
Net −$1,466,459. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-04-30 | BIENAIME JEAN JACQUES Chief Executive Officer | Exercise or conversion | +1,000 | $37.46 | $37K | 303,498 |
| 2021-04-30 | BIENAIME JEAN JACQUES Chief Executive Officer | Exercise or conversion · Stock Option (Right to buy Common Stock) | −1,000 | 139,000 | ||
| 2021-04-23 | BIENAIME JEAN JACQUES Chief Executive Officer | Exercise or conversion | +10,000 | $26.49 | $265K | 312,498 |
| 2021-04-23 | BIENAIME JEAN JACQUES Chief Executive Officer | Sale | −10,000 | $79.34 | $793K | 302,498 |
| 2021-04-23 | BIENAIME JEAN JACQUES Chief Executive Officer | Exercise or conversion · Stock Option (Right to buy Common Stock) | −10,000 | 58,513 | ||
| 2021-04-22 | BIENAIME JEAN JACQUES Chief Executive Officer | Exercise or conversion | +10,000 | $26.49 | $265K | 312,498 |
| 2021-04-22 | BIENAIME JEAN JACQUES Chief Executive Officer | Sale | −10,000 | $78.91 | $789K | 302,498 |
| 2021-04-22 | BIENAIME JEAN JACQUES Chief Executive Officer | Exercise or conversion · Stock Option (Right to buy Common Stock) | −10,000 | 68,513 | ||
| 2021-04-19 | Davis George Eric EVP, General Counsel | Exercise or conversion | +2,709 | $26.49 | $72K | 71,149 |
| 2021-04-19 | Davis George Eric EVP, General Counsel | Sale | −2,709 | $79.58 | $216K | 68,440 |
| 2021-04-19 | Davis George Eric EVP, General Counsel | Exercise or conversion · Stock Option (Right to buy Common Stock) | −2,709 | 0 | ||
| 2021-04-15 | LAWLIS V BRYAN Director | Exercise or conversion | +7,500 | $26.49 | $199K | 26,350 |
| 2021-04-15 | LAWLIS V BRYAN Director | Sale | −7,500 | $76.90 | $577K | 18,850 |
| 2021-04-15 | LAWLIS V BRYAN Director | Exercise or conversion · Stock Option (Right to buy Common Stock) | −7,500 | 0 | ||
| 2021-04-08 | Ajer Jeffrey Robert EVP, Chief Commercial Officer | Sale | −1,537 | $78.81 | $121K | 58,250 |
| 2021-04-01 | Mueller Brian EVP, Chief Financial Officer | Sale | −5,692 | $76.30 | $434K | 31,016 |
| 2021-03-30 | Ajer Jeffrey Robert EVP, Chief Commercial Officer | Sale | −1,652 | $74.79 | $124K | 59,787 |
| 2021-03-24 | Ajer Jeffrey Robert EVP, Chief Commercial Officer | Sale | −1,181 | $76.30 | $90K | 61,439 |
| 2021-03-22 | Mueller Brian EVP, Chief Financial Officer | Shares withheld for taxes | −516 | $78.52 | $41K | 36,708 |
| 2021-03-22 | FUCHS HENRY J President, Worldwide R&D | Shares withheld for taxes | −2,454 | $78.52 | $193K | 106,142 |
Page 30 of 36 · 707 trades